Covid-19 vaccination drive starts in Assam
Guwahati/UNI: The Covid-19 vaccination drive started in Assam on Saturday along with other parts of the country.
Covid-19: Bharat Biotech rolls out India's indigenous vaccine Covaxin
Hyderabad/IBNS: A day after the Serum Institute of India (SII) rolled out its vaccine against Covid-19, the first batch of India's indigenous remedy Covaxin, made by Bharat Biotech, left Hyderabad for 11 cities on Wednesday morning, media reports said.
Air India, SpiceJet, GoAir, and IndiGo transport 56.5 lakh doses of SII's Covishield across India
New Delhi/IBNS: The first batches of coronavirus vaccine began rolling out on early Tuesday from the Pune facility of Serum Institute of India with a total of 56.5 lakh doses to be transported during the day by Air India, SpiceJet, GoAir, and IndiGo, said media reports.
India fights COVID-19: First consignment of Covishield vaccines leaves Serum Institute Pune
Pune/UNI: Three temperature-controlled trucks rolled out of the Serum Institute's gates shortly before 5 am and left for Pune airport, from where the vaccines will be flown to different parts of India.
Indian govt signs contract with Serum Institute for 11 million doses of Covishield
New Delhi/IBNS: The government has placed an initial order of 11 million doses of Covishield manufactured by Serum Institute of India (SII), media reports said.
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine
Pune: Serum Institute of India, the largest vaccine manufacturer in the world by doses, announces the launch of India’s first indigenously developed pneumococcal vaccine – Pneumosil in the presence of Dr. Harsh Vardhan, Minister of Health and Family Welfare on Monday.
Serum Institute applies for emergency approval of Covishield
New Delhi/IBNS: The Serum Institute of India (SII) has applied for an emergency approval from the Indian government of its vaccine against Covid-19, named Covishield.
COVID-19 vaccine is safe, says Serum Institute of India on side effect claims
Pune-based Serum Institute of India's (SII) said its 'COVISHIELD' vaccine is safe and immunogenic after a volunteer claimed that he suffered neurological and psychological side effects after taking a shot of the vaccine.
India reports over 48,000 Covid-19 cases in 24 hours, active cases fall below 6 lakh
New Delhi/IBNS: India, the second worst Covid-19-affected country in the world, reported over 48,000 new cases in the last 24 hours, taking the overall tally of infections to 80,88,851.
Covid-19 vaccine could be ready by December: Serum Institute's Adar Poonawalla
New Delhi/Pune/IBNS: Giving a hope to 1.3 billion people of India, vaccine manufacturer Serum Institute of India (SII)'s chief Adar Poonawalla has said the Oxford University's Covid-19 vaccine can be made available in the country by December 2020.
New Delhi: Serum Institute of India CEO Adar Poonawalla on Saturday asked whether the Indian government will have Rs. 80,000 crores over the next one year to buy and distribute the COVID-19 vaccine to everyone in India.
After DCGI's show-cause notice, Serum Institute pauses Covid-19 vaccine trial
New Delhi/IBNS: Serum Institute of India (SII) on Thursday paused the trial of Covid-19 vaccine a day after it was served a show-cause notice by the Drugs Controller General of India (DCGI) for not informing the central drug regulator about the pause of study testing in other countries, media reports said.
Dhaka: Beximco Pharmaceuticals Limited, the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, and the Serum Institute of India Pvt. Ltd (SII), the world’s largest vaccine producer,on Sunday announced an agreement in principle for a cooperation and distribution agreement to develop a COVID-19 vaccine, for which Beximco will be the exclusive supplier in Bangladesh.
India adds close to 61,000 Covid-19 cases, 848 deaths in 24 hours
New Delhi/IBNS: India, which has been badly-hit by the Novel Coronavirus pandemic, added close to 61,000 fresh infections on Tuesday.